Mirum Pharmaceuticals Highlights Encouraging Data For Rare Liver Disease Therapy From Two Mid-Stage Studies
Portfolio Pulse from Vandana Singh
Mirum Pharmaceuticals announced positive interim results from two Phase 2b studies evaluating volixibat for primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC). The VANTAGE study showed significant improvement in pruritus and fatigue with no new safety signals. The VISTAS study will continue with the selected dose. MIRM shares rose 14.6% following the announcement.
June 17, 2024 | 2:53 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mirum Pharmaceuticals reported positive interim results from two Phase 2b studies for volixibat, showing significant improvements in pruritus and fatigue for PBC patients and meeting safety and efficacy criteria for PSC patients. MIRM shares rose 14.6% following the announcement.
The positive interim results from the Phase 2b studies for volixibat indicate significant clinical benefits and no new safety concerns, which is likely to boost investor confidence and drive the stock price up. The 14.6% increase in MIRM shares reflects this positive sentiment.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100